Cargando…

Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open‐label, single‐dose, parallel‐group study

AIMS: The study objective was to evaluate the pharmacokinetics of the selective progesterone receptor modulator vilaprisan in participants with hepatic impairment. Additionally, the safety and tolerability of vilaprisan were investigated. METHODS: In this phase 1, open‐label, nonrandomised, parallel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chattopadhyay, Niladri, Riecke, Kai, Ligges, Sandra, Zimmermann, Torsten, Halabi, Atef, Schultze‐Mosgau, Marcus‐Hillert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710501/ https://www.ncbi.nlm.nih.gov/pubmed/31112623 http://dx.doi.org/10.1111/bcp.13992

Ejemplares similares

Pharmacokinetics and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Participants With Renal Impairment
por: Schultze‐Mosgau, Marcus‐Hillert, et al.
Publicado: (2020)

Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug–Drug Interaction Potential
por: Schultze-Mosgau, Marcus-Hillert, et al.
Publicado: (2018)

The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive—A randomized controlled trial
por: Schultze‐Mosgau, Marcus‐Hillert, et al.
Publicado: (2020)

Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women
por: Liu, Hongzhong, et al.
Publicado: (2020)

Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview
por: Schultze-Mosgau, Marcus-Hillert, et al.
Publicado: (2021)

Effect of Food Intake on the Pharmacokinetics of the Selective Progesterone Receptor Modulator Vilaprisan: A Randomized Clinical Study in Healthy Postmenopausal Women
por: Schultze‐Mosgau, Marcus‐Hillert, et al.
Publicado: (2020)

Effect of the Novel Selective Progesterone Receptor Modulator Vilaprisan on Ovarian Activity in Healthy Women
por: Schütt, Barbara, et al.
Publicado: (2017)

Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure–response modelling and simulation
por: Sutter, Gabriele, et al.
Publicado: (2021)

Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies
por: Möller, Carsten, et al.
Publicado: (2018)

Pharmacokinetics of serelaxin in patients with severe renal impairment or end‐stage renal disease requiring hemodialysis: A single‐dose, open‐label, parallel‐group study
por: Dahlke, Marion, et al.
Publicado: (2015)

Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study
por: Wiebe, Sabrina, et al.
Publicado: (2016)

Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open‐label, single‐dose, parallel‐group study
por: Chen, Xinhui, et al.
Publicado: (2021)

Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials
por: Bentz Damholt, Birgitte, et al.
Publicado: (2021)

Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open‐Label, Single‐Dose, Parallel Group Study
por: Song, Ivy, et al.
Publicado: (2022)

Pharmacokinetics and Safety of Multiple-Dose Alpelisib in Participants with Moderate or Severe Hepatic Impairment: A Phase 1, Open-Label, Parallel Group Study
por: Marbury, Thomas, et al.
Publicado: (2023)

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
por: Fontes, Magda S. C., et al.
Publicado: (2022)

A Phase 1, Open‐Label, Parallel‐Group, Single‐Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment
por: Taylor, Lesley, et al.
Publicado: (2019)

A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
por: Tayo, Bola, et al.
Publicado: (2019)

The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies
por: Kusawake, Tomohiro, et al.
Publicado: (2017)

The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension
por: Gessler, Tobias, et al.
Publicado: (2017)

Effect of renal impairment on the pharmacokinetics of prucalopride: a single- dose open-label Phase I study
por: Smith, William B, et al.
Publicado: (2012)

An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline
por: Kovacs, Steven J., et al.
Publicado: (2020)

Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel
por: Schilling, Uta, et al.
Publicado: (2022)

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
por: Schnell, David, et al.
Publicado: (2014)

Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function
por: Kunz, Christina, et al.
Publicado: (2016)

An Open‐Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics
por: Li, Yan, et al.
Publicado: (2018)

Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects
por: Li, Guofei, et al.
Publicado: (2018)

A phase‐1, open‐label, single‐dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment
por: Csonka, Denes, et al.
Publicado: (2016)

Single‐Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

Single‐Dose Pharmacokinetics and Safety of Ubrogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial
por: Boinpally, Ramesh, et al.
Publicado: (2022)

A phase I, open‐label, single‐dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib
por: Gao, Ling, et al.
Publicado: (2023)

A non-linear pharmacokinetic-pharmacodynamic relationship of metformin in healthy volunteers: An open-label, parallel group, randomized clinical study
por: Chung, Hyewon, et al.
Publicado: (2018)

A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function
por: Ermer, James, et al.
Publicado: (2016)

Ethnic comparison of pharmacokinetics of (18)F-florbetaben, a PET tracer for beta-amyloid imaging, in healthy Caucasian and Japanese subjects
por: Senda, Michio, et al.
Publicado: (2014)

Similar pharmacokinetics of three dosing regimens comprising two oral delayed‐release mesalamine formulations in healthy adult volunteers: Randomised, open‐label, parallel‐group study
por: Vande Casteele, Niels, et al.
Publicado: (2020)

Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies
por: Tomkinson, Helen, et al.
Publicado: (2011)

In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [(18)F]FEDAA1106
por: Takano, Akihiro, et al.
Publicado: (2013)

An Open‐Label Study to Evaluate the Effect of Eluxadoline on the Single‐Dose Pharmacokinetics of Midazolam in Healthy Participants
por: Boinpally, Ramesh, et al.
Publicado: (2022)

Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study
por: Fineman, Mark S., et al.
Publicado: (2023)

Management of dental extraction in patients with Haemophilia A and B: A report of 58 extractions
por: Peisker, Andre, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_670dbdt6ct97ljbiot81vuti8a